ALX Oncology Overview
- Year Founded
-
2015
- Status
-
Public
- Employees
-
48
- Stock Symbol
-
ALXO
- Investments
-
1
- Share Price
-
$1.08
- (As of Thursday Closing)
ALX Oncology General Information
Description
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
Contact Information
Website
www.alxoncology.comCorporate Office
- 323 Allerton Avenue
- South San Francisco, CA 94080
- United States
Corporate Office
- 323 Allerton Avenue
- South San Francisco, CA 94080
- United States
ALX Oncology Timeline
ALX Oncology Stock Performance
As of 12-Nov-2026, ALX Oncology’s stock price is $1.08. Its current market cap is $149M with 138M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.08 | $1.12 | $0.86 - $2.66 | $149M | 138M | 1.16M | -$1.13 |
ALX Oncology Financials Summary
As of 30-Jun-2026, ALX Oncology has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 146,733 | 10,752 | (50,658) | 561,368 |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (83,008) | (103,351) | (141,615) | (169,053) |
| Net Income | (80,890) | (101,695) | (134,850) | (160,805) |
| Total Assets | 160,820 | 59,046 | 147,775 | 242,553 |
| Total Debt | 9,705 | 9,749 | 9,904 | 9,639 |
ALX Oncology Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
ALX Oncology Comparisons
Industry
Financing
Details
ALX Oncology Competitors (3)
One of ALX Oncology’s 3 competitors is Zymeworks, a Formerly VC-backed company based in Vancouver, Canada.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Zymeworks | Formerly VC-backed | Vancouver, Canada | ||||
| Precigen | Formerly VC-backed | Germantown, MD | ||||
| Numab Therapeutics | Venture Capital-Backed | Horgen, Switzerland |
ALX Oncology Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
ALX Oncology Patents
ALX Oncology Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026187830-A1 | Combination therapies for treating cancer | Pending | 04-Mar-2025 | ||
| WO-2026187611-A1 | Cd47 inhibitory agent and bcma nk cell engager combination therapy | Pending | 01-Mar-2025 | ||
| WO-2026050757-A2 | Calicheamicin derivatives and antibody-drug conjugates thereof | Pending | 30-Aug-2024 | ||
| WO-2026050757-A3 | Calicheamicin derivatives and antibody-drug conjugates thereof | Pending | 30-Aug-2024 | ||
| AU-2023371678-A1 | Exatecan derivatives and antibody-drug conjugates thereof | Pending | 04-Nov-2022 | A61K47/6851 |
ALX Oncology Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
ALX Oncology Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
ALX Oncology Acquisitions (1)
ALX Oncology’s most recent deal was a Merger/Acquisition with ScalmiBio for . The deal was made on 04-Oct-2021.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| ScalmiBio | 04-Oct-2021 | Merger/Acquisition | Biotechnology |
ALX Oncology ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
24.37 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,585
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
ALX Oncology FAQs
-
When was ALX Oncology founded?
ALX Oncology was founded in 2015.
-
Where is ALX Oncology headquartered?
ALX Oncology is headquartered in South San Francisco, CA.
-
What is the size of ALX Oncology?
ALX Oncology has 48 total employees.
-
What industry is ALX Oncology in?
ALX Oncology’s primary industry is Drug Discovery.
-
Is ALX Oncology a private or public company?
ALX Oncology is a Public company.
-
What is ALX Oncology’s stock symbol?
The ticker symbol for ALX Oncology is ALXO.
-
What is the current stock price of ALX Oncology?
As of 12-Nov-2026 the stock price of ALX Oncology is $1.08.
-
What is the current market cap of ALX Oncology?
The current market capitalization of ALX Oncology is $149M.
-
Who are ALX Oncology’s competitors?
Zymeworks, Precigen, and Numab Therapeutics are competitors of ALX Oncology.
-
What is ALX Oncology’s annual earnings per share (EPS)?
ALX Oncology’s EPS for 12 months was -$1.13.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
